H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients

Biol Psychiatry. 2000 Jul 15;48(2):167-8. doi: 10.1016/s0006-3223(00)00872-6.

Abstract

Background: Olanzapine is temporally associated, in a number of patients with schizophrenia, with weight gain. H(2) antagonists, like nizatidine, have been shown to control appetite in overweight patients.

Methods: A patient with olanzapine temporally associated weight gain was treated with nizatidine as "add-on" therapy.

Results: Nizatidine treatment was associated with good control and subsequent reduction of weight after 4 to 5 weeks of therapy in a patient with repetitive episodes of weight gain during olanzapine treatment. Olanzapine was otherwise well tolerated and effective in controlling psychopathology.

Conclusions: H(2) antagonist treatment with olanzapine may be a valid medical strategy in preventing and/or reducing weight gain in patients with schizophrenia. Controlled studies are recommended to confirm this observation.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Benzodiazepines
  • Brief Psychiatric Rating Scale
  • Histamine H2 Antagonists / pharmacology*
  • Histamine H2 Antagonists / therapeutic use*
  • Humans
  • Male
  • Nizatidine / pharmacology*
  • Nizatidine / therapeutic use*
  • Obesity / chemically induced*
  • Obesity / drug therapy*
  • Olanzapine
  • Pirenzepine / adverse effects
  • Pirenzepine / analogs & derivatives*
  • Schizophrenia, Paranoid / diagnosis
  • Schizophrenia, Paranoid / drug therapy*
  • Time Factors
  • Weight Gain / drug effects*

Substances

  • Histamine H2 Antagonists
  • Benzodiazepines
  • Pirenzepine
  • Olanzapine
  • Nizatidine